AC Immune and Bayer Schering Pharma collaborate in brain imaging for Alzheimer’s Disease

12-Oct-2009 - Switzerland

AC Immune SA announced that it has entered a collaboration with Bayer Schering Pharma on the diagnostic imaging of Alzheimer´s Disease. Bayer´s novel positron emission tomography (PET) tracer florbetaben will be applied for imaging beta-Amyloid plaques in the brain of patients undergoing the Phase I clinical testing of AC Immune´s Alzheimer´s vaccine ACI-24. This is the first time this PET tracer will be tested in treated Alzheimer’s patients.

Prof. Andrea Pfeifer, CEO of AC Immune said, “This collaboration with Bayer adds further value to our Alzheimer´s vaccine ACI-24. The adoption of a diagnostic imaging substance visualizing the deposition of beta-Amyloid that is targeted by our vaccine can be an important parameter for dose selection, and will provide useful complementary data. There is a key trend in the industry to co-develop therapy guiding diagnostics alongside drugs for patients. We look forward to working with Bayer´s experts in this ground-breaking collaboration.”

Other news from the department business & finance

Most read news

More news from our other portals

So close that even
molecules turn red...

See the theme worlds for related content